HLB resubmits FDA application for liver cancer treatment
Korean drugmaker HLB has resubmitted its application for U.S. approval of a combination therapy for advanced liver cancer, renewing its push to bring the target treatment to market after addressing regulatory concerns raised earlier this year. The Korean biopharmaceutical company said Monday that its U.S. subsidiary, Elevar Therapeutics, and Chinese partner Hengrui Pharma submitted the…
Read original article on Korea Times News →Related news
-
Hyosung Chemical brings high-performance plastics to Europe for EVs, robots
-
Saudi airport passenger terminal is struck again, a day after 12 were killed
-
Ex-US lawmaker underscores Seoul-Washington ties
-
Claude emerges as fastest-growing AI skill in Korean job postings
-
Military manpower agency chief voices regret over Asian Games footballers' gloating about military exemption
-
Naver Map to offer voice guidance on Meta, Google, Samsung smart glasses
-
Global poverty index rises for first time since its 2010 creation
-
Gaon Cable to make nuclear power plant cables in US